Platelet-Poor Plasma vs PRP in NYC: Why the Formulation of Your Injection Decides the Result
Not all plasma injections are the same. Two vials drawn from the same patient, spun in the same centrifuge, can produce biologically different products — one thick with platelets and white blood cells, the other nearly clear. The clear one is platelet-poor plasma (PPP), and for years it was discarded as waste. It is now used deliberately in certain protocols, and patients researching regenerative treatment in New York City are increasingly asking what the difference is and whether they are getting the right formulation.
This guide explains what platelet-rich plasma (PRP) and platelet-poor plasma actually contain, where each has evidence behind it, how leukocyte content and platelet concentration change outcomes, and what questions to ask before you consent to an injection. At Regen Health Physicians, Dr. Ajit Dhaliwal treats formulation as a clinical decision rather than a fixed recipe — the preparation is matched to the tissue being treated.
What is in a tube of blood after it spins
A standard blood draw separates under centrifugal force into three zones: red blood cells at the bottom, a thin white "buffy coat" of leukocytes and platelets in the middle, and plasma on top. Where the operator draws from determines the product.
Platelet-rich plasma (PRP)
PRP is plasma concentrated with platelets above baseline. Whole blood contains roughly 150,000–400,000 platelets per microliter. Clinically useful PRP generally lands between 2x and 6x baseline, meaning 600,000 to well over 1,000,000 platelets per microliter depending on the system and the number of spins.
Platelets matter because their alpha granules release a coordinated set of growth factors on activation: platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1), and epidermal growth factor (EGF). These signal fibroblasts and tenocytes to proliferate, recruit stem cells to the area, and stimulate new capillary growth. PRP is not a painkiller — it is a biological stimulus that asks tissue to start a repair cycle it had stalled on.
Platelet-poor plasma (PPP)
PPP is the supernatant left above the platelet layer after a second, harder spin. It is low in platelets and leukocytes but still contains the plasma protein environment: fibrinogen, albumin, immunoglobulins, and circulating IGF-1 bound to its carrier proteins. Fibrinogen is the key ingredient. When activated, PPP forms a fibrin matrix — a scaffold rather than a growth factor bolus.
That distinction is the whole story. PRP signals. PPP scaffolds. Confusing the two leads to disappointing results in both directions: a scaffold where you needed a signal, or a burst of inflammatory signalling where you needed structure.
Where PPP is used on purpose
PPP is not simply diluted PRP, and it is not a way to stretch a sample. It has legitimate, specific applications.
Fibrin membranes and gels in aesthetics
When PPP is heated or allowed to polymerize, it forms an autologous fibrin gel used as a volumizing and structural material — sometimes marketed as "plasma gel" or used alongside PRF (platelet-rich fibrin) in facial work. Because it is derived from the patient, there is no filler-related hypersensitivity risk, though the volume effect is temporary compared with hyaluronic acid. This is a scaffold role, layered into regenerative aesthetic protocols rather than replacing them.
Post-procedure tissue sealing and adhesion control
Fibrin-rich PPP is used as a biologic sealant in surgical and post-injection settings to reduce bleeding and limit adhesion formation between healing tissue planes.
Ocular surface and mucosal applications
Autologous serum and PPP-derived eye drops have a reasonable literature base in severe dry eye and persistent corneal epithelial defects, where the goal is a protein-rich, non-inflammatory surface environment.
A deliberate low-inflammation alternative
Some patients respond to PRP with a pronounced inflammatory flare — days of aching swelling as the growth factor cascade engages. In a small subset with sensitized pain states, a lower-inflammation plasma product may be tolerated when concentrated PRP is not. This is an individualized decision, not a general preference.
Where PRP is the right choice
For most musculoskeletal, scalp, and skin-remodeling work, the growth factor payload is the active ingredient, and PPP is underpowered.
Tendon and ligament injury
Chronic tendinopathy is a degenerative, disorganized-collagen problem, not an acute inflammatory one. Randomized data in lateral elbow tendinopathy and gluteal tendinopathy support leukocyte-rich PRP over corticosteroid at 6–12 months, with steroid often looking better early and worse later. Tendon needs the PDGF/TGF-β signal to reorganize collagen. Our regenerative orthopedic program uses ultrasound guidance so the injectate reaches the pathologic tissue rather than the surrounding sheath.
Knee osteoarthritis
Multiple meta-analyses of intra-articular PRP in mild-to-moderate knee osteoarthritis show superiority over hyaluronic acid and saline on pain and function scores at 6–12 months, with effect size tied to platelet dose and the number of injections. Results in advanced, bone-on-bone disease are substantially weaker — a finding worth discussing honestly during a joint and back pain consultation.
Androgenetic alopecia and hair thinning
PRP in the scalp works by extending the anagen (growth) phase and improving perifollicular vascularity. Trials consistently show increases in hair density and caliber over 3–6 months with a loading series. PPP has no meaningful role here — the follicle needs VEGF and IGF-1 signalling, which is exactly what is removed. See our precision hair restoration program for how the series is structured.
Skin remodeling
Microneedling combined with PRP drives dermal fibroblast activity and collagen type I production. Studies comparing microneedling plus PRP with microneedling alone favor the PRP arm for acne scarring and texture.
Leukocyte content: the variable most patients never hear about
PRP is subdivided by white blood cell content, and this matters more than the PRP-versus-PPP question in day-to-day practice.
Leukocyte-rich PRP (LR-PRP)
Contains neutrophils and monocytes along with platelets. The neutrophil fraction adds proteolytic enzymes and a stronger inflammatory signal. This appears advantageous in tendon, where a controlled inflammatory phase seems to be part of the remodeling response. It also produces more post-injection soreness.
Leukocyte-poor PRP (LP-PRP)
Depleted of neutrophils. The evidence trend for intra-articular use — inside a knee or hip joint — favors leukocyte-poor preparations, because neutrophil-driven inflammation in a synovial joint can aggravate the very environment you are trying to calm. Several systematic reviews report better outcomes and fewer adverse reactions with LP-PRP in knee osteoarthritis.
A practical summary of how we think about formulation:
| Target tissue | Preferred product | Rationale | |---|---|---| | Chronic tendinopathy | Leukocyte-rich PRP | Controlled inflammation aids collagen remodeling | | Intra-articular (knee, hip) | Leukocyte-poor PRP | Avoids neutrophil-driven synovial irritation | | Scalp / hair | Leukocyte-poor PRP | Growth factor signalling without excess flare | | Skin / microneedling | PRP or PRF | Fibroblast stimulation, collagen induction | | Volumizing, sealing, ocular surface | PPP / fibrin gel | Scaffold and protein environment, not signalling |
Dose, activation, and the reasons results vary between clinics
When two patients report opposite experiences with "PRP," the difference is usually in the details below.
Platelet dose actually delivered
Total platelet dose equals concentration multiplied by volume. A 3 mL injection of 2x PRP delivers a fraction of the platelets in a 6 mL injection of 5x PRP. Dose-response relationships have been reported in knee osteoarthritis, with a threshold in the range of a few billion platelets per treatment. If a clinic cannot tell you the concentration factor or the draw volume, they cannot tell you the dose.
Single versus double spin
Single-spin systems are fast and yield moderate concentration with variable leukocyte content. Double-spin protocols yield higher concentration and allow deliberate separation of the PPP layer. PPP produced this way can be retained intentionally — for example, as a fibrin scaffold — rather than discarded.
Anticoagulant and activation choices
ACD-A versus sodium citrate affects platelet viability and injectate pH. Calcium chloride or thrombin activation triggers immediate growth factor release and gel formation, which suits scaffolding applications; unactivated PRP relies on collagen contact in tissue to trigger release, which suits tendon and joint injection.
Imaging guidance
Blind injection into a region of pain is not the same as targeted delivery into a pathologic tendon or a specific joint compartment. Ultrasound guidance materially improves accuracy for hip, shoulder, and small-joint targets.
Patient-side variables
NSAIDs are generally stopped roughly 7–10 days before and 2 weeks after injection because they blunt the prostaglandin-mediated repair cascade. Smoking, uncontrolled hyperglycemia, low ferritin, and vitamin D deficiency all reduce tissue response. Baseline platelet count and hydration status affect the yield of the draw itself. Addressing these upstream issues is part of our chronic disease and metabolic optimization work when the initial workup identifies them.
What a well-run plasma treatment looks like
- Evaluation. History, examination, imaging review, and diagnostic ultrasound where indicated. The diagnosis determines the formulation — not the reverse.
- Labs where relevant. CBC, ferritin, HbA1c or fasting insulin, vitamin D, and inflammatory markers for patients with poor healing histories.
- Draw and preparation. Typically 30–60 mL of whole blood, prepared by a protocol chosen for the target tissue, with the concentration factor documented.
- Injection. Ultrasound-guided where anatomy warrants. Expect pressure and aching rather than sharp pain.
- Early recovery. Soreness peaks at 24–72 hours, especially with leukocyte-rich preparations. Acetaminophen and ice are acceptable; NSAIDs are avoided.
- Loading and progression. Tendon and joint work is typically 1–3 sessions spaced 4–6 weeks apart; scalp protocols use a 3–4 session loading series with maintenance. Progressive loading rehabilitation is not optional for tendon — the biology needs mechanical input to organize.
- Reassessment. Meaningful change is assessed at 8–12 weeks, not at two weeks. Some patients benefit from adjunctive peptide therapy to support connective tissue and recovery between sessions.
Honest limits
PRP does not regrow cartilage in advanced osteoarthritis. It does not replace surgery for a complete tendon rupture, a mechanically unstable joint, or a large full-thickness rotator cuff tear. Response rates in appropriately selected patients are good but not universal — a realistic expectation is meaningful improvement in a majority, with a minority who see little change. PPP, similarly, is a scaffold material with modest and temporary volumizing effect, not a growth factor therapy.
Any clinic promising guaranteed results, or using "stem cell" language for what is in fact a plasma injection, is describing marketing rather than biology.
Questions worth asking before you consent
- Is this PRP or PPP, and why was that chosen for my tissue?
- What is the platelet concentration factor, and what volume will be injected?
- Is the preparation leukocyte-rich or leukocyte-poor?
- Single spin or double spin? Is the product activated before injection?
- Will the injection be image-guided?
- How many sessions does this protocol involve, and when will we reassess?
- What is the rehabilitation plan afterward?
A clinic that answers these specifically is making clinical decisions. A clinic that cannot is running one recipe for every patient.
Talk to a physician about which plasma product fits your case
Dr. Ajit Dhaliwal sees patients in New York City and Salt Lake City for regenerative orthopedic, hair, aesthetic, and longevity care, including Muse stem cell therapy for selected regenerative indications. If you have been offered a plasma injection and want to understand the formulation — or you have had PRP before without result and want to know why — book a consultation and bring your prior records and imaging.
---
Medical disclaimer: This article is for educational purposes and does not constitute medical advice, diagnosis, or treatment. PRP and PPP are autologous blood-derived preparations; indications, evidence quality, and outcomes vary by condition. Individual results differ. Consult a qualified physician about your specific circumstances before starting any treatment.
